|
Course #98410 - $15-
| A) | Contact the transplant surgeon to review the patient's medical history before calling the OPO. | ||
| B) | Defer the donation discussion until the family brings up the topic independently. | ||
| C) | Refer the patient to the OPO and allow the OPO medical director to determine medical suitability. | ||
| D) | Rule the patient ineligible for donation based on the cancer history and document accordingly. |
| A) | Brain death declaration is required as a prerequisite before any tissue recovery can occur. | ||
| B) | Registration in the state donor registry is required before tissue donation authorization. | ||
| C) | Solid organ donors are the only patients from whom tissue donation can be pursued. | ||
| D) | Tissue donation can occur up to 12 to 24 hours after cardiac death, expanding the potential donor pool. |
| A) | Cardiac death following withdrawal of life-sustaining treatment precedes organ procurement. | ||
| B) | Declaration of brain death by a physician independent of the transplant team precedes organ procurement. | ||
| C) | Organ procurement begins while the patient is maintained on mechanical ventilatory support throughout. | ||
| D) | Simultaneous consent for donation and withdrawal of treatment must be obtained before any procurement. |
| A) | A documented observation period of at least 48 hours following the neurological injury | ||
| B) | Confirmation of bilateral fixed and dilated pupils on bedside assessment | ||
| C) | Documentation of an isoelectric pattern on electroencephalography | ||
| D) | Exclusion of CNS-depressant drugs and absence of pharmacologic paralysis |
| A) | A clinical team member prefers additional objective evidence to support the bedside examination | ||
| B) | Clinical examination or apnea testing cannot be completed due to the patient's medical condition | ||
| C) | Family members request independent confirmation before accepting the brain death diagnosis | ||
| D) | Institutional policy mandates two physician declarations for the brain death determination |
| A) | Separating the notification of brain death from the subsequent conversation about donation | ||
| B) | Structuring communications so the OPO coordinator leads all family meetings independently | ||
| C) | Waiting until the family independently raises the topic of donation before any discussion | ||
| D) | Withholding clinical information until the family support coordinator is fully briefed |
| A) | Engage a professional medical interpreter for all donation-related discussions. | ||
| B) | Involve a bilingual family member who can serve as an interpreter and provide emotional support. | ||
| C) | Provide translated written materials and allow the family adequate time for independent review. | ||
| D) | Simplify the discussion by limiting it to yes-or-no questions the family can respond to directly. |
| A) | Both values are elevated above their respective target ranges. | ||
| B) | Both values fall below their respective target ranges. | ||
| C) | The CVP is within the target range, but the MAP is below the target range. | ||
| D) | The MAP is within the target range, but the CVP is below the target range. |
| A) | It eliminates the need for hormonal replacement therapy in hemodynamically unstable donors. | ||
| B) | It is the most potent vasopressor available for maintaining systolic blood pressure targets. | ||
| C) | It simultaneously addresses diabetes insipidus, provides vasomotor support, and reduces catecholamine requirements. | ||
| D) | It targets renal vasomotor pathways preferentially, without affecting cardiac output or vascular tone. |
| A) | Dexamethasone administered as an intravenous bolus | ||
| B) | Hydrocortisone administered as a continuous intravenous infusion | ||
| C) | Insulin administered as a continuous intravenous infusion | ||
| D) | Triiodothyronine administered as a continuous intravenous infusion |